Date post: | 17-Dec-2015 |
Category: |
Documents |
Upload: | horatio-terry |
View: | 213 times |
Download: | 0 times |
TM
Pediatric Asthma Evaluation & Management
Bradley E. Chipps, MD, FAAPCapital Allergy & Respiratory Disease CenterSacramento, CA
TM
Prepared for your next patient.
TM
Disclaimers Statements and opinions expressed are those of the authors and not
necessarily those of the American Academy of Pediatrics.
Mead Johnson sponsors programs such as this to give healthcare professionals access to scientific and educational information provided by experts. The presenter has complete and independent control over the planning and content of the presentation, and is not receiving any compensation from Mead Johnson for this presentation. The presenter’s comments and opinions are not necessarily those of Mead Johnson. In the event that the presentation contains statements about uses of drugs that are not within the drugs' approved indications, Mead Johnson does not promote the use of any drug for indications outside the FDA-approved product label.
TM
Definition of AsthmaA chronic inflammatory disease of the airways with the following clinical features:
Episodic and/or chronic symptoms of airway obstruction
Bronchial hyperresponsiveness to triggers
Evidence of at least partial reversibility of the airway obstruction
Alternative diagnoses are excluded
TM
Diagnosis1. History
2. Pulmonary function tests (PFTs)
3. Challenge studies
TM
Wheezing—Asthma?Wheezing with upper respiratory infections is very common in small children, but:Many of these children will not develop asthma.Asthma medications may benefit patients who wheeze whether or not they have asthma.
All that wheezes is not asthma.
TM
Cough—Asthma?Consider asthma in children with:Recurrent episodes of cough with or without wheezingNocturnal awakening because of coughCough that is associated with exercise/playCough without wheeze is often not asthma
Cough may be the only symptompresent in patients with asthma.
Goldsobel AB, Chipps BE. Cough in the pediatric population. J Pediatr. 2010;156(3):352–358
TM
Asthma Predictive Index Identify high risk children (2 and 3 years of age):• ≥4 wheezing episodes in the past year
(at least one must be MD diagnosed)
PLUS
OR One major criterion• Parent with asthma• Atopic dermatitis• Aero-allergen
sensitivity
Two minor criteria• Food sensitivity• Peripheral
eosinophilia (≥4%) • Wheezing not
related to infectionModified from: Castro-Rodriguez JA, Holberg CJ, Wright AL, et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1403–1406
TM
Objective Evaluation of Asthma Physical examination
Pulmonary function
Bronchoprovocation
Validated control tools
TM
Defining Asthma Severity and Control
1) 0–4 years
2) 5–11 years
3) 12 years and older
TM
How Can Asthma Control Be Measured?
AsthmaControl
Inflammation?Direct or indirect?
Lung function? Daytime
symptoms?
Utilization of healthcare resources?
Nighttime awakenings?
Functional status?
Missed work and/or school?
Patient self-report of control?
Use of “quick relief” inhaler
and/or nebulizer?
Asthma control test is a trademark of QualityMetric Incorporated.
TM
Asthma Control Cannot be Assessedat a Single Time Point
Approximately one-third of both adult and pediatric subjects had 15 or more changes in their asthma severity classification based upon peak expiratory flow (PEF) during the 12-week studies.
Chipps BE, Span JD, Sorkness CA, et al. Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists. J Pediatr. 2006;148(4):517–521; Calhoun WJ, Sutton LB, Emmett A, et al. Asthma variability in patients previously treated with beta2-agonists alone. J Allergy Clin Immunol. 2003;112(6):1088–1094
35
30
25
20
15
10
5
00 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15-1915-19 20-24 25+
% o
f Pati
ents
Number of Changes Over Weeks 1–12
TM
Classifying Asthma Severity and InitiatingTreatment in Children 0 to 4 Years of Age
Adapted from: National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed July 5, 2012
TM
Assessing Asthma Control and AdjustingTherapy in Children 0 to 4 Years of Age
Adapted from: National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed July 5, 2012
TMTest for Respiratory and Asthma Control in Kids (TRACK)
TM
Stepwise Approach for Managing Asthma in Children 0 to 4 Years of Age
Adapted from: National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed July 5, 2012
TM
Classifying Asthma Severity and InitiatingTreatment in Children 5 to 11 Years of Age
TM
Assessing Asthma Control and Adjusting Therapy in Children 5 to 11 Years of Age
TM
Childhood Asthma Control Test™
TM
Stepwise Approach for Managing Asthmain Children 5 to 11 Years of Age
Adapted from: National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis andManagement of Asthma. US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed July 5, 2012
TM
Classifying Asthma Severity and InitiatingTreatment in Youth ≥12 Years of Age and Adults
TM
Assessing Asthma Control in Children≥12 Years of Age and Adults
TM
Asthma Control Test™ (ACT)
TM
Stepwise Approach for Managing Asthmain Children 12 Years of Age and Adults
TM
Infants and Young Children—When to Start Controllers
>3 episodes of wheezing in the last year, and Parental history of asthma or physician diagnosis of
eczemaOr 2 of the following: Physician diagnosis of allergic rhinitis, wheezing apart
from colds, peripheral eosinophilia Courses of oral steroids more often than every 6 weeks Symptoms >2 times per week, nocturnal symptoms >2
times per month
TM
Step-down TherapyStep down once control is achieved:After 2–3 months25% reduction over 2–3 months
Follow-up monitoring:Every 1–6 monthsAssess symptoms.Review medication use.Objective monitoring (PEF or spirometry)Review medication.
TM
Step-up Therapy Indications: Symptoms, need for quick-relief
medication, exercise intolerance, decreased lung function
• May need a short course of oral steroids.
Continue to monitor.• Follow and reassess every 1–6 months• Step down when appropriate.
TM
Phenotypic Expressions of ChildhoodWheezing Disorders
1. Viral induced wheezing
2. Severe intermittent wheezing
3. Exercise bronchospasm/asthma
4. Persistent asthma
5. Severe asthma
TM
Viral Induced Wheezing
1. Triggered by viral infections
2. Non-atopic
3. Remission in childhood
TM
Infants
TM
Intermittent Inhaled Corticosteroids (ICS)in Infants with Episodic Wheezing
Single randomized double-blind study N=411 infants with a 3-day history of wheezing Infants treated with budesonide 400 µg/d or placebo
for 2 weeks Primary outcome variables were:
• Number of symptom free days• Number of days free from rescue medication use• Number of episodes• Number of treatments with open label budesonide
Bigaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Eng J Med. 2006;354(19):1998–2005
TMIntermittent ICS in Infants:Withdrawal Due to Persistent Wheezing
50
40
30
20
10
00 100 200 300 400 600 700500 800 900
Perc
en
tag
e o
f C
hild
ren
Wit
hd
raw
nB
ecau
se o
f P
ers
iste
nt
Wh
eezin
g
Days after Randomization
Budesonide
Placebo
P=0.41
No. at Risk
Budesonide 149 115 78 27
Placebo 145 114 92 27
Progression from episodic to persistent wheezing. Results were not significant.Bigaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Eng J Med. 2006;354(19):1998–2005
TM
Role of Viral Infections
TM
Rhinovirus (RV) Wheezing versusRespiratory Syncytial Virus (RSV) Wheezing in
First 3 Years of Life and Asthma at 6 Years of Age
Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008; 178(7):667–672
TM
Forced Expiratory Volume in 1 Second (FEV1)Percent Predicted
TM
RV Infections and the Development of Asthma RV infections can produce more than upper airway
illnesses during infancy. Children who develop asthma by 6 years of age have a
significantly increased burden of viral wheezing illnesses in early life.
Pulmonary function abnormalities at 6 years of age are most significantly associated with early childhood wheezing illnesses due to RV (not RSV).
Of all outpatient wheezing viral illnesses in early life, those due to RV are most significant.
TM
Oral Prednisolone for Preschool Childrenwith Acute Virus-induced Wheezing
Randomized, double-blind, placebo-controlled trial comparing a 5-day course of oral prednisolone (10 mg daily for children 10–24 months and 20 mg daily for older children) versus placebo in 700 children between the ages of 10 and 60 months.
No difference in 7-day symptom scores, albuterol use, or readmission Primarily non-atopic and 60% first time wheezers
Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med. 2009;360(4):329–338
TM
Severe IntermittentWheezing
TM
Acute Intermittent Management Strategies (AIMS)—Primary Hypothesis
In young children with recurrent severe wheezing, intervention with an ICS or leukotriene receptor antagonist (LTRA) at the onset of respiratory tract illness (RTI)-associated symptoms will increase the proportion of episode-free days over a 12-month period compared with conventional therapy.*
*Conventional therapy—inhaled bronchodilator followed by the sequential addition of systemiccorticosteroids
TMEpisodic Use of an ICS or LTRA in Preschool Childrenwith Moderate-to-Severe Intermittent Wheezing
Montelukast 4 mg daily + Placebo ICS + -agonist
At first sign of RTI symptoms x 7 days
Study Overview
Budesonide 1 mg bid+ Placebo LTRA + -
agonist
RandomizationRun in
Acute Intermittent Management Strategies (AIMS)
Randomized, multicenter, double-blind, placebo-controlled 1 year trial 238 children, 12–59 months, with recurrent episodes of intermittent wheezing• 2 episodes in the previous year • 2 urgent care visits, 2 oral steroid courses, or 1 of each Primary outcome = episode free days Secondary outcomes = symptoms scores during illnesses and oral corticosteroids (OCS)
useBacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127–1135
Placebo LTRA + Placebo ICS + -agonist
TM
1° Outcome—Mean Proportion ofEpisode Free Days
Proportion of episode free days adjusted for age group, API status, center
TM
Maintenance versus Intermittent InhaledSteroids in Wheezing Toddlers (MIST) Study
1. 12 month R, DB, active control: 278 children(12–53 months)
2. 4 episodes of wheezing last year: Positive mAPI 1 episode: OCS, emergency department,
urgent care or hospital
3. Primary outcome: Exacerbation with OCS
TM
Run-in: 2 weeks Treatment Phase: 52 weeks
Pbo run-in nightly +
Albuterol PRN
Randomized
Treatment Group
Nightly, except during RTI
During RTIs only for 7 days
Daily low dose budesonide
0.5 mg PM Pbo AM
0.5 mg PM
Intermittent high dose budesonide
Pbo PM 1.0 mg AM
1.0 mg PM
TM
MIST Study
1. Exacerbations 0.95/patient year; p=0.6
2. Similar time to first exacerbation; p=0.87
3. No difference in treatment failures or episode free days
4. Height=0.26 cm average difference; weight=0.16 Kg average difference
TM
Diagnosis of Exercise-induced Bronchospasm (EIB) / Exercise-
induced Asthma (EIA)
TM
EIA Therapy—General Principles EIA may reflect suboptimally controlled asthma,
which may require adjustment of overall therapy of asthma.
Goal: Facilitate normal activity levels, including competitive sports.
Individualize therapy.
Child needs to understand and be a partner in therapy.
TM
Diagnosis of EIB Normal PFT at rest
No other stimulus for bronchospasm
Most common in allergic rhinitis patients
Dx: 10% decrease FEV1 after 8 minutes of exercise at 90% maximum predicted heart rate
Rx: B-agonist before exercise, LTRA daily
TM
Diagnosis of EIA Normal or obstructive PFT at rest
Patient has other stimuli for asthma symptoms.
Patient has both inflammatory and bronchospasm component.
Dx: Same criteria
Rx: ICS, LTRA, ICS/long-acting beta antagonist (LABA) daily, B-agonist before exercise
TM
Persistent Asthma
TM
Multicentre Allergy Study (MAS)1. Birth cohort: 1314
• 13-year follow up: 441 (33.6% all visits)• No wheeze 1st year: 315 (74%)
2. Early wheezers: 126• No wheeze (4–13 years): 79 (68%)• Initial wheeze: 43 (34%)• Persistent wheeze: 4 (3%)
3. Wheeze 3–6 years: 40 (13%)
4. Wheeze 6–13 years: 42 (13%)Matricardi PM, Illi S, Grüber C, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J. 2008;32(3):585–392
TM
The Prevalence of Wheezing VariesDepending on Age and Atopic Status
Atopic (n=94)Non-atopic (n=59)
80
70
60
50
40
30
20
10
01 2 3 4 5 6 7 8 9 10 11 12 13
Age (years)
Prevalence (%)
Illi S, von Mutius E, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006;368(9537):763–770
TM
Time of Sensitization and Degree of Exposure to Indoor Allergens and Lung Function Impairment at 7 Years of Age
100
95
90
85
80
75
700
105
110
115
FEV1
(% pred)
MEF50
(% pred)
NS S/LE S/HE NS S/LE S/HE
100
959085
8075
700
105
110115
120
p=0.009 p=0.003
FEV1 (% pred)
MEF50 (% pred)
NS S/LE S/HE NS S/LE S/HE
Illi S, von Mutius E, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006;368(9537):763–770
TM
Melbourne Epidemiological Study
Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002;109(2):189–194
TMA Longitudinal, Population-based, Cohort Studyof Childhood Asthma Followed to Adulthood
Sears MR, Greene JM, Willan AR, et al. A longitudinal population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003;349(15):1414–1422
TM
ICS Therapy in Preschool Children Multicenter, double-blind, randomized placebo controlled
study designed to determine if ICS therapy can modify the subsequent development of asthma in high risk children
Children with a positive asthma predictive index (2–3 years of age, N=285) treated with either fluticasone 88 µg BID or placebo for 2 years followed by a year of observation
Primary outcome variable: Proportion of episode free days
Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006; 354(19):1985–1997
TMFluticasone Had No Carryover EffectDuring the Observation Period
p=0.006 p=0.781.00
0.95
0.90
0.85
0.80
0.750.00
Pro
po
rtio
n o
f E
pis
od
e-fr
ee D
ays
Treatment Period Observation Period
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36
Months
The increase in symptom free days in the fluticasone cohort during the treatment period waslost in the 12 months subsequent during the observation period.
Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med.2006;354(19):1985–1997
Fluticasone
Placebo
TM
The Need for Oral CorticosteroidsAll Children Children Not Receiving
Supplementary MedicationObservation
Treatment
Fluticasone
Placebo
0
25
50
75
100
0 6 12 3018 24 36
No
Nee
d fo
r a F
irst c
ours
eof
Pre
dnis
olon
e (%
of c
hild
ren)
Months
Observation
Placebo
Fluticasone
0 24 26 28 30 32 34 36Months
No. at Risk
Fluticasone 143 102 80 66 57 42
Placebo 142 87 62 57 50 41
No. at Risk
Fluticasone 132 88
Placebo 130 85
0
25
50
75
100
TM
The Need for Supplementary Controller Meds:No Difference at 36 months
No. at Risk
Fluticasone 143 131 118 116 113 99
Placebo 142 125 103 99 93 86
No. at Risk
Fluticasone 132 111
Placebo 130 105
The fluticasone group had less of a need for supplementary medications during the treatment period (p<0.01). By the end of the observation period (36 months), thegroups were indistinguishable (P=0.99)
Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006; 354(19):1985–1997
0
25
50
75
100
0 6 12 3018 24 360
25
50
75
100
0 24 26 28 30 32 34 36
Months Months
Fluticasone Fluticasone
Placebo Placebo
No
Nee
d fo
r Sup
plem
enta
ryAs
thm
a-Co
ntro
ller M
edic
ation
(% o
f chi
ldre
n)
TM
Changes in Height from Baseline and Between Groups
Change in height from baseline represented by the panel on the left. The difference betweengroups with associated p-values represented on the right. At the end of 24 months the fluticasone group averaged 1.1 cm less than the placebo group. At the end of the observation period (36 months) the difference between groups was 0.7 cm.
Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006; 354(19):1985–1997
0
5
10
15
20
0 10 20 30
Chan
ge in
Hei
ght f
rom
Base
line
(cm
)
Months
-1.5
-1.0
-0.5
0
0 10 20 30
Month 1 4 8 12 16 20 24 28 32 36
P value 0.81
0.07
0.0001
<0.001
<0.001
<0.001
<0.001
<0.0010.0
03
0.008
Diff
eren
ce in
Hei
ght C
hang
ebe
twee
n Fl
utica
sone
and
Plac
ebo
Gro
ups
(cm
)
TM
Summary and Clinical Implications
Based on the results of the Prevention of Early Asthma in Kids (PEAK) study:
ICS are effective in improving asthma-like symptom burden, exacerbations, and lung function in high risk toddlers.
Continuous ICS therapy for 2 years once discontinued does not modify the natural history of asthma in early childhood.
TM
START
INHALED STEROID TREATMENTAS REGULAR THERAPY
IN EARLY ASTHMA
The World’s Largest Study in Asthma Therapy
Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076
TM
Primary Study Objective and Primary Variables Examines effect of early intervention with ICS on
evolution of newly diagnosed asthma Primary outcome:• Time to first severe asthma-related event (SARE) during first 3
years of study• A severe event requiring hospitalization or emergency
treatment due to worsening of asthma or death due to asthma
Secondary outcome:• Change in postbronchodilator FEV1 Intent to treat analysis
Pauwels RA, Busse WW, O’Byrne PM, et al. The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design. Control Clin Trials. 2001;22(4):405–419
TM
Double-blind (Part A) andOpen-label (Part B) Design
AdultsPulmicort 400 g once daily
+ usual asthma therapyChildren (6–10 y of age)
Pulmicort 200 g once daily+ usual asthma therapy
Part A – Pulmicort therapy
Part B: Open-label
Part A – Reference therapy
AdultsPulmicort 400 g once daily
+ usual asthma therapy
Children (6–10 y of age)Pulmicort 200 g once daily
+ usual asthma therapyAdults and Children
Placebo once daily + usual asthma therapy
Year 0 1 2 3 4 5Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
TM
Time to First SARE44% (95% CI, 29–55%) reduced risk of first SARE*
Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076
0.10
0.08
0.06
0.04
0.02
0.00
0 1 2 3
Reference therapyBudesonide therapy
Cum
ulati
ve P
roba
bilit
y
*Hazard ratio = 0.56; P<.0001.
TM
Patients Requiring Additional Corticosteroids*
*Inhaled, oral, or systemic
Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076
0
10
20
30
40
50
60
Budesonide Therapy Reference Therapy
% o
f P
atie
nts
TM
Changes in Postbronchodilator FEV1 Over 3 Years
Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076
TM
Early Intervention with Budesonide inMild Persistent Asthma
Sullivan SD. Early intervention with budesonide in mild persistent asthma—the START study. Presented at the European Respiratory Society (ERS). Stockholm, Sweden, 2002
TM
Early Intervention with Budesonide inMild Persistent Asthma
Budesonide therapy reduces the risk of a severe asthma exacerbation by 44% in patients with mild persistent asthma.
Daily treatment with low dose budesonide decreases the need for oral corticosteroids in mild persistent asthma.
Budesonide daily improves asthma control• More symptom free days• Less additional asthma medicationPauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076
TM
BADGER Trial
TM
BADGER Trial1. 182 children (6–17 years of age), uncontrolled
asthma, FP 100 µg BID, triple crossover design,16-week period
2. FP 250 µg BIDFP 100 µg + SALM 50 µg BIDFP 100 µg BID + MTL 5 or 10 mg daily
3. 3 outcomes• Exacerbations• Symptom free days• FEV1 (Pre)
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Primary Predictors of a DifferentialResponse to Step-up Therapy
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Primary Predictors of a DifferentialResponse to Step-up Therapy
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Secondary Predictors of a DifferentialResponse to Step-up Therapy
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Enrollment, Outcomes, and Schedule of Evaluations
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Pairwise Comparisons
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Probability of Best Response
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985
TM
Severe Asthma
TM
Severe Asthma Refractory
Difficult to control asthma
Uncontrolled asthma refractory to conventional treatment
Frequent exacerbations
? Distinct phenotype or subgroup
TM
Reasons for Failure to Achieve Control Compliance
Asthma heterogeneity
Wrong diagnosis
Wrong target
Failure to deliver drug to the target site
TM
Demographic and clinicalcharacteristics of children
and adolescents with severe ordifficult-to-treat asthma
TM
TENOR Study Design 3-year, multi-center, observational study
• Patients continued to receive medications and treatments administered for their asthma as indicated by their physician.
4,756 patients enrolled between January and October 2001
• 6 years of age or older
• 283 sites across the US
Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004; 92(1):32–39
TM
Objectives Primary objective
• Describe the natural history of patients considered by physicians to have “severe” or “difficult-to-treat” asthma.
Secondary objectives• Examine relationship between features of asthma,
treatments, and outcomes.• Observe frequency of comorbid conditions.• Examine the relationship between immunoglobulin
and disease.
TM
Methods Cross-sectional baseline data analyzed
TENOR patients between 6 and 17 years of age included (N=1,261)
Patients categorized into 4 age groups by gender:
Age group (years)
Males(N=791)
n (%)
Females(N=470)
n (%)
Total(N=1,261)
n (%)6-8 145 (18) 88 (19) 233 (18)
9-11 282 (36) 120 (26) 402 (32)12-14 240 (30) 171 (36) 411 (33)15-17 124 (16) 91 (19) 215 (17)
Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119(5):1156–1163
TM
Spirometry by Age and Gender
Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119(5):1156–1163
TM
Medication Use by Age
*Based on test for linear trend, a statistically significant age trend (P <.05) was seen for methylxanthines and long-acting -agonists.
Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119(5):1156–1163
TM
Healthcare Utilization by Long-term Controller Use:6–11 and 12–17 Years of Age
Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119(5):1156–1163
TM
Summary―Predicting Persistence of Wheezing1. Family history of asthma
2. Recurrent lower airway symptoms in infancy
3. Absence of nasal symptoms at 1 year
4. Atopic sensitization before 4 years and early exposure
5. Eczema
6. Exposure to ETS
7. Females
8. Acetaminophen ?
9. Vitamin D ?
TM
Thank You
TM
For more information… On this topic and a host of other topics, visit www.pediatriccareonline.org
. Pediatric Care Online is a convenient electronic resource for immediate expert help with virtually every pediatric clinical information need. Must-have resources are included in a comprehensive reference library and time-saving clinical tools.
• Haven't activated your Pediatric Care Online trial subscription yet?It's quick and easy: simply follow the steps on the back of the card you received from your Mead Johnson representative.
• Haven't received your free trial card?Contact your Mead Johnson representative or call 888/363-2362 today.